“The dosing of the first human with such an investigational base editing medicine represents a significant achievement by our team and for the field of gene editing,” Sekar Kathiresan, the cofounder ...

The partnership aims to leverage Editas’ CRISPR Cas12a genome editing systems with Genevant’s proprietary lipid nanoparticle ...

With their backing, we are well positioned to make significant strides toward delivering novel gene editing therapeutics, including those targeting CNS diseases with high unmet need.” ...